Search results for "ADULT"

showing 10 items of 17453 documents

Redefining outcomes in immune TTP: an international working group consensus report

2021

Abstract Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic microangiopathy caused by autoantibody-mediated severe deficiency of ADAMTS13. Standardized definitions of response, exacerbation, remission, and relapse were initially proposed in 2003 and modified by the International Working Group for TTP in 2017. These definitions, which have been widely used in clinical practice and research, are based primarily on the platelet count and are benchmarked against the timing of discontinuation of therapeutic plasma exchange (TPE). They do not incorporate ADAMTS13 activity or the temporizing effects on the platelet count of caplacizumab, a novel anti–von W…

Adult0301 basic medicinemedicine.medical_specialtyConsensusThrombotic microangiopathyExacerbation[SDV]Life Sciences [q-bio]ImmunologyThrombotic thrombocytopenic purpuraMEDLINEADAMTS13 Protein030204 cardiovascular system & hematologyBiochemistry03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRecurrencehemic and lymphatic diseasesvon Willebrand FactorHumansMedicineClinical significanceIntensive care medicinePlasma ExchangePurpura Thrombotic ThrombocytopenicPlatelet Countbusiness.industryDisease ManagementCell BiologyHematologySingle-Domain Antibodiesmedicine.diseaseADAMTS133. Good healthDiscontinuationTreatment Outcome030104 developmental biologyFemaleCaplacizumabbusinessBlood
researchProduct

Cyclophosphamide plus Epidoxorubicin and 5-Fluorouracil with Folinic Acid as a Novel Treatment in Metastatic Breast Cancer: Preliminary Results of a …

1991

Twenty consecutive patients with advanced breast cancer were treated with a combination of cyclophosphamide 600 mg/m2 i.v. on day 1, epidoxorubicin 75 mg/m2 on day 1, and 5-fluorouracil 375 mg/m2 i.v. with folinic acid 200 mg/m2 i.v. on days 1----3. The overall response rate was 60%, with 10% of patients showing a complete response with a mean duration of 11.1 + months, and 50% of patients a partial response of 7.4 + months. A stabilization of 5.2 + months was obtained in 20% of cases, while 20% of patients progressed. The most frequently observed toxicity was leukopenia, while expected mucosal toxicities were rather mild.

Adult0301 basic medicinemedicine.medical_specialtyCyclophosphamide030106 microbiologyLeucovorinPhases of clinical researchBreast NeoplasmsGastroenterologyMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisInfusions IntravenousCyclophosphamideEpirubicinPharmacologyLeukopeniabusiness.industryRemission InductionCancerMiddle Agedmedicine.diseaseMetastatic breast cancerSurgeryInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisDrug EvaluationFemaleFluorouracilmedicine.symptombusinessmedicine.drugJournal of Chemotherapy
researchProduct

Topical application of the Wnt/β-catenin activator methyl vanillate increases hair count and hair mass index in women with androgenetic alopecia

2016

Activation of the WNT/β-catenin pathway has emerged as a potential therapeutic target in androgenetic alopecia (AGA). Methyl vanillate (MV) - a safe plant-derived ingredient - has been recently shown to activate the WNT/β-catenin signaling. Objectives Two distinct substudies were conducted. First, we designed a 6-month, uncontrolled, open-label clinical study to investigate whether topically applied MV may increase hair count and hair mass index (HMI) in female AGA. Second, we conducted a molecular study on the effect of MV on WNT10B mRNA expression in scalp biopsies of women with AGA. A total of 20 Caucasian women (age range: 25-57 years) with AGA (Sinclair grade 1-2) were included. The re…

Adult0301 basic medicinemedicine.medical_specialtyGene ExpressionPilot ProjectsDermatologyGenética humanaAdministration Cutaneous03 medical and health sciencesMolecular levelProto-Oncogene ProteinsInternal medicinemedicineHumansMass indexRNA MessengerAdverse effectWnt Signaling Pathwaybeta CateninVanillic AcidActivator (genetics)business.industryWnt signaling pathwayAlopeciaWNT/β-cateninMiddle AgedWnt Proteins030104 developmental biologyEndocrinologymedicine.anatomical_structureMethyl vanillateCateninScalpFemalebusinessHair
researchProduct

Inflammation and coronary artery disease: The exercise paradox

2018

Adult0301 basic medicinemedicine.medical_specialtyImmunologyMEDLINEInflammationCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyBiochemistryCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansImmunology and AllergyExercise physiologyExerciseMolecular BiologyInflammationbusiness.industryHematologymedicine.disease030104 developmental biologyExercise TestCardiologymedicine.symptombusinessCytokine
researchProduct

The clinical utility of PGD with HLA matching: a collaborative multi-centre ESHRE study

2018

Study question Has PGD-HLA been successful relative to diagnostic and clinical efficacy? Summary answer The diagnostic efficacy of PGD-HLA protocols was found lower in this study in comparison to published PGD-HLA protocols and to that reported for general PGD by ESHRE (78.5 vs 94.1% and vs 92.6%, respectively), while the clinical efficacy has proven very difficult to assess due to inadequate follow-up of both the ART/PGD and HSCT procedure outcomes. What is known already The first clinical cases for PGD-HLA were reported in 2001. It is now a well-established procedure, with an increasing number of cycles performed every year. However, PGD-HLA is still offered by relatively few PGD centres,…

Adult0301 basic medicinemedicine.medical_specialtyPediatricsMEDLINEOocyte RetrievalFertilization in Vitro03 medical and health sciences0302 clinical medicinePregnancymedicineHumansGenetic TestingPreimplantation DiagnosisRetrospective StudiesGenetic testing030219 obstetrics & reproductive medicinemedicine.diagnostic_testbusiness.industryHistocompatibility TestingRehabilitationHematopoietic Stem Cell TransplantationPregnancy OutcomeObstetrics and GynecologyRetrospective cohort studyTissue DonorsTransplantationPregnancy rate030104 developmental biologyReproductive MedicineFemaleOutcomes researchbusinessLive birthCohort studyHuman Reproduction
researchProduct

Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haema…

2016

Patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT) are at risk of developing invasive fungal infections (IFIs). Even with introduction of oral triazole antifungal agents (fluconazole, itraconazole, posaconazole and voriconazole) IFI-associated morbidity and mortality rates and economic burden remain high. Despite their proven efficacy, it is currently unknown which is the most cost-effective antifungal prophylaxis (AFP) agent. To determine the costs and outcomes associated with AFP, a decision-analytic model was used to simulate treatment in a hypothetical cohort of 1000 patients undergoing alloHSCT from the perspective of the Spanish National Health System. …

Adult0301 basic medicinemedicine.medical_specialtyPosaconazoleAntifungal AgentsCost effectivenessItraconazoleCost-Benefit Analysismedicine.medical_treatment030106 microbiologyDermatologyHematopoietic stem cell transplantationDecision Support Techniques03 medical and health sciencesInternal medicinemedicineHumansFluconazoleVoriconazolebusiness.industryMortality rateHematopoietic Stem Cell TransplantationGeneral MedicineTriazolesSurgeryTransplantationInfectious DiseasesSpainVoriconazoleItraconazolebusinessInvasive Fungal InfectionsFluconazolemedicine.drugMycoses
researchProduct

Hemostatic Abnormalities in Patients With Severe Preeclampsia

2007

Preeclampsia is the most common medical disorder of pregnancy. Early onset preeclampsia is defined as presentation of hypertension and proteinuria before 34 weeks of gestation. Alterations of endothelial cells and fibrin deposition in microvasculature lead to enhanced activation of the coagulation cascade and impaired fibrinolysis associated with multiple organ dysfunctions. Plasma samples were obtained from 50 patients with severe preeclampsia before 34 weeks of gestation and in 61 patients with late preeclampsia. Factor VIIIR:Ag, fibrinogen, D-dimer, and thrombomodulin increased with advanced pregnancy. The platelet count is very important because of the close correlation with the activa…

Adult0301 basic medicinemedicine.medical_specialtyPregnancy Trimester ThirdThrombomodulinmedicine.medical_treatmentComorbidity030204 cardiovascular system & hematologyFibrinogenThrombomodulinGastroenterologyPreeclampsiaFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicinePre-EclampsiaPregnancyInternal medicineFibrinolysismedicineHumansreproductive and urinary physiologyHemostasisPregnancyProteinuriaPlatelet Countbusiness.industryAntithrombinFibrinogenHematologyGeneral MedicineBlood Coagulation Disordersmedicine.diseasefemale genital diseases and pregnancy complications030104 developmental biologyembryonic structuresImmunologyGestationFemaleEndothelium Vascularmedicine.symptombusinessmedicine.drugClinical and Applied Thrombosis/Hemostasis
researchProduct

Endocarditis due to Abiotrophia defectiva, a biofilm-related infection associated with the presence of fixed braces

2017

Abstract Rationale: Endocarditis with Abiotrophia defectiva represents 4.3% to 6% of all streptococcal endocarditis. The article presents diagnosis issues and the complexity of the treatment. Patient concerns: We present the case of a female white patient, aged 26 years, who developed infectious endocarditis caused by A defectiva, in the last trimester of pregnancy, a biofilm-related infection associated with the presence of fixed braces. Diagnoses: The diagnosis of infectious endocarditis was confirmed by the cardiac ultrasound examination that revealed a voluminous vegetation on the mitral valve, and acute mitral regurgitation caused by chordae tendinae rupture, and also by isolating Abio…

Adult0301 basic medicinemedicine.medical_specialtyProsthesis-Related Infectionsmedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticsbiofilm03 medical and health sciences0302 clinical medicinePregnancyAbiotrophiaMitral valvemedicineHumansEndocarditisClinical Case Report030212 general & internal medicinePregnancy Complications InfectiousAbiotrophia defectivaGram-Positive Bacterial InfectionsAbiotrophia defectivaBracesinfectious endocarditisbiology4900business.industryMitral valve replacementEndocarditis BacterialGeneral MedicineAbiotrophiabiology.organism_classificationmedicine.diseaseSurgerymedicine.anatomical_structureEmbolismBiofilmsInfective endocarditisFemalebusinessResearch ArticleMedicine
researchProduct

A Roma founder BIN1 mutation causes a novel phenotype of centronuclear myopathy with rigid spine

2018

ObjectiveTo describe a large series of BIN1 patients, in which a novel founder mutation in the Roma population of southern Spain has been identified.MethodsPatients diagnosed with centronuclear myopathy (CNM) at 5 major reference centers for neuromuscular disease in Spain (n = 53) were screened for BIN1 mutations. Clinical, histologic, radiologic, and genetic features were analyzed.ResultsEighteen patients from 13 families carried the p.Arg234Cys variant; 16 of them were homozygous for it and 2 had compound heterozygous p.Arg234Cys/p.Arg145Cys mutations. Both BIN1 variants have only been identified in Roma, causing 100% of CNM in this ethnic group in our cohort. The haplotype analysis confi…

Adult0301 basic medicinemedicine.medical_specialtyRomaNeuromuscular diseaseAdolescentPopulationMallory BodiesCompound heterozygosityArticleMuscular DystrophiesCohort StudiesYoung Adult03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProspective StudiesCentronuclear myopathyChildeducationProspective cohort studyAdaptor Proteins Signal TransducingRetrospective Studieseducation.field_of_studybusiness.industryTumor Suppressor ProteinsHaplotypeNuclear ProteinsRetrospective cohort studyMiddle Agedmedicine.diseaseFounder EffectPhenotype030104 developmental biologyScoliosisSpainMutation[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Neurology (clinical)business030217 neurology & neurosurgeryMyopathies Structural CongenitalFounder effect
researchProduct

Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum

2019

Abstract: Lifestyle modification is the foundation of treatment recommendations for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The design of clinical trials in NASH may be impeded by the lack of a systematic approach to identify and evaluate how lifestyle changes and/or modifications influence clinical trial outcomes and associated endpoints. Furthermore, there are additional uncertainties regarding the methods that can be utilised to better characterise and quantify lifestyle variables - which can influence disease activity and alter trial endpoints - to allow for comparisons of trial outcomes across different phases of research and/or within drug-c…

Adult0301 basic medicinemedicine.medical_specialtyStandard of careContext (language use)DiseaseBody Mass IndexDisease activity03 medical and health sciences0302 clinical medicineLifestyle modificationNon-alcoholic Fatty Liver DiseaseHumansMedicineIntensive care medicineExerciseClinical Trials as TopicHepatologybusiness.industryBody WeightFatty livermedicine.diseaseExercise TherapyClinical trialTreatment Outcome030104 developmental biology030211 gastroenterology & hepatologyHuman medicineDiet HealthyWaist CircumferenceSteatohepatitisbusinessJournal of Hepatology
researchProduct